Erscheint 6 Ausgaben pro Jahr
ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X
Indexed in
Aerosol Treatment of Cystic Fibrosis
ABSTRAKT
Different aerosol therapies have been employed to treat the underlying cause and symptoms of cystic fibrosis (CF) during the past two decades. A summary of the main elements of the disease and aerosol treatments employed in clinical care and experimental trials are presented. Methods of aerosol generation and characterization are reviewed. Suggestions for improving the current treatments are provided.
-
Tam Jasmine M., McConville Jason T., Williams Robert O., Johnston Keith P., Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution, Journal of Pharmaceutical Sciences, 97, 11, 2008. Crossref
-
Wang Ying-Ying, Lai Samuel K., Suk Jung Soo, Pace Amanda, Cone Richard, Hanes Justin, Addressing the PEG Mucoadhesivity Paradox to Engineer Nanoparticles that “Slip” through the Human Mucus Barrier, Angewandte Chemie International Edition, 47, 50, 2008. Crossref
-
Plosker Greg L., Aztreonam Lysine for Inhalation Solution, Drugs, 70, 14, 2010. Crossref
-
Wang Ying-Ying, Lai Samuel K., Suk Jung Soo, Pace Amanda, Cone Richard, Hanes Justin, Addressing the PEG Mucoadhesivity Paradox to Engineer Nanoparticles that “Slip” through the Human Mucus Barrier, Angewandte Chemie, 120, 50, 2008. Crossref
-
Hindle Michael, Aerosol Drug Delivery, in Pharmaceutical Sciences Encyclopedia, 2010. Crossref
-
Karnaukhova E., Ophir Y., Golding B., Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use, Amino Acids, 30, 4, 2006. Crossref
-
Tang Benjamin C., Fu Jie, Watkins D. Neil, Hanes Justin, Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo, Biomaterials, 31, 2, 2010. Crossref
-
Hickey Anthony J., Lu Dongmei, Ashley Elizabeth Dodds, Stout Jason, Inhaled Azithromycin Therapy, Journal of Aerosol Medicine, 19, 1, 2006. Crossref
-
Vargas José M., McBride Amber A., Plumley John B., Fichou Yann, Memon Tosifa A., Shah Vichiksha, Cook Nathaniel C., Akins Brian A., Rivera Antonio C., Smolyakov Gennady A., O’Brien James R., Adolphi Natalie L., Smyth Hugh D. C., Osiński Marek, Synthesis and characterization of core/shell Fe3O4/ZnSe fluorescent magnetic nanoparticles, Journal of Applied Physics, 109, 7, 2011. Crossref
-
Plosker Greg L., Aztreonam Lysine for Inhalation Solution in Cystic Fibrosis†, Pediatric Drugs, 13, 2, 2011. Crossref
-
O’Riordan Thomas G, Aerosol delivery devices and obstructive airway disease, Expert Review of Medical Devices, 2, 2, 2005. Crossref
-
Boylan Nicholas J., Suk Jung Soo, Lai Samuel K., Jelinek Raz, Boyle Michael P., Cooper Mark J., Hanes Justin, Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation, Journal of Controlled Release, 157, 1, 2012. Crossref
-
Newman Stephen P., IMAGING PULMONARY DRUG DELIVERY, in Drug Delivery Applications of Noninvasive Imaging, 2013. Crossref
-
Hickey Anthony J., Back to the Future: Inhaled Drug Products, Journal of Pharmaceutical Sciences, 102, 4, 2013. Crossref
-
Connors Patricia M., Ulles Monica M., The Physical, Psychological, and Social Implications of Caring for the Pregnant Patient and Newborn With Cystic Fibrosis, The Journal of Perinatal & Neonatal Nursing, 19, 4, 2005. Crossref
-
Hokey David A, Wachholder Robert, Darrah Patricia A, Bolton Diane L, Barouch Dan H, Hill Krystal, Dheenadhayalan Veerabadran, Schwander Stephan, Godin C Steven, Douoguih Macaya, Pau Maria Grazia, Seder Robert A, Roederer Mario, Sadoff Jerald C, Sizemore Donata, A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine, Human Vaccines & Immunotherapeutics, 10, 8, 2014. Crossref
-
Hickey Anthony J., General Conclusion, in Inhaled Pharmaceutical Product Development Perspectives, 2018. Crossref
-
Sultana Shaheen, Talegaonkar Sushma, Nishad Dhruv Kumar, Mittal Gaurav, Ahmad F.J., Bhatnagar Aseem, Alpha ketoglutarate nanoparticles: A potentially effective treatment for cyanide poisoning, European Journal of Pharmaceutics and Biopharmaceutics, 126, 2018. Crossref
-
Price Dominique N., Kunda Nitesh K., Muttil Pavan, Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing, KONA Powder and Particle Journal, 36, 2019. Crossref
-
Price Dominique N., Muttil Pavan, Delivery of Therapeutics to the Lung, in Lung Innate Immunity and Inflammation, 1809, 2018. Crossref
-
Kukut Hatipoglu Manolya, Hickey Anthony J., Garcia-Contreras Lucila, Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs, International Journal of Pharmaceutics, 549, 1-2, 2018. Crossref
-
Osiński Marek, Brandt Yekaterina I., Armijo Leisha M., Kopciuch Michael, Withers Nathan. J., Cook Nathaniel C., Adolphi Natalie L., Smolyakov Gennady A., Smyth Hugh D. C., Efficacy of Tobramycin Conjugated to Superparamagnetic Iron Oxide Nanoparticles in Treating Cystic Fibrosis Infections, MRS Proceedings, 1617, 2013. Crossref
-
Garcia-Contreras Lucila, Bioavailability of inhaled compounds, in Inhalation Aerosols, 2019. Crossref
-
Price Dominique N., Stromberg Loreen R., Kunda Nitesh K., Muttil Pavan, In Vivo Pulmonary Delivery and Magnetic-Targeting of Dry Powder Nano-in-Microparticles, Molecular Pharmaceutics, 14, 12, 2017. Crossref
-
Suk Jung Soo, Lai Samuel K, Boylan Nicholas J, Dawson Michelle R, Boyle Michael P, Hanes Justin, Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine, Nanomedicine, 6, 2, 2011. Crossref
-
Hickey Anthony James, Stewart Ian Edward, Inhaled antibodies: Quality and performance considerations, Human Vaccines & Immunotherapeutics, 18, 2, 2022. Crossref